Adlai Nortye (NASDAQ:ANL) Trading Down 5.3% Following Insider Selling

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) shares dropped 5.3% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $14.30 and last traded at $14.2640. 84,559 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 395,832 shares. The stock had previously closed at $15.06.

Specifically, CFO Xiaofeng Ye sold 5,667 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75. Following the completion of the sale, the chief financial officer owned 147,757 shares of the company’s stock, valued at $2,105,537.25. The trade was a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Xiaofeng Ye sold 6,000 shares of the firm’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $13.98, for a total value of $83,880.00. Following the completion of the transaction, the chief financial officer owned 153,424 shares in the company, valued at $2,144,867.52. The trade was a 3.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Analyst Ratings Changes

Several brokerages have recently weighed in on ANL. JonesTrading started coverage on Adlai Nortye in a report on Thursday, May 14th. They set a “buy” rating and a $22.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Adlai Nortye in a research report on Monday, June 22nd. They set an “overweight” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Oppenheimer initiated coverage on Adlai Nortye in a research report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 target price for the company. Finally, Wall Street Zen raised shares of Adlai Nortye from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Adlai Nortye currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

Adlai Nortye Price Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. The firm has a 50 day moving average price of $12.00 and a 200-day moving average price of $11.16.

Hedge Funds Weigh In On Adlai Nortye

Institutional investors and hedge funds have recently modified their holdings of the company. Seven Fleet Capital Management LP acquired a new position in shares of Adlai Nortye during the 2nd quarter worth about $1,302,000. Braidwell LP purchased a new stake in shares of Adlai Nortye in the second quarter valued at about $9,145,000. Boone Capital Management LLC acquired a new stake in Adlai Nortye during the 2nd quarter worth approximately $2,971,000. ADAR1 Capital Management LLC purchased a new position in Adlai Nortye in the 1st quarter valued at $816,000. Finally, Affinity Asset Advisors LLC purchased a new position in Adlai Nortye during the first quarter worth about $1,140,000. Institutional investors and hedge funds own 35.21% of the company’s stock.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.